All Party Parliamentary Group for Life Sciences CSR letter to the Chancellor, Business Secretary and Science Ministers
November 10, 2015Manufacturing and Production, Research and Development Chancellor, Comprehensive Spending Review, George Osborne
Dear Mr Osborne,Ahead of the forthcoming Comprehensive Spending Review I am sure you will have received many letters from across …
Janssen buys licence to diabetes and obesity drugs from Hanmi
November 10, 2015Manufacturing and Production, Research and Development Janssen, diabetes, hanmi
Janssen could spend up to a billion dollars to buy for novel clinical stage biologics to treat diabetes and obesity. …
FDA warnings create woe for Indian drugmakers
November 10, 2015Manufacturing and Production CGMP, Dr Reddy's, Dr. Reddy's, FDA, India, Sun Pharma, manufacturing, production
Recent enforcement action has taken its toll on the fortunes of several Indian pharmaceutical manufacturers, with Sun Pharmaceuticals and Dr. …
Sanofi Pasteur ‘actively exploring’ universal flu vaccine
November 10, 2015Manufacturing and Production, Research and Development SEEK, Sanofi Pasteur, influenza, universal flu vaccine
Sanofi Pasteur is developing a universal, cross-reactive antigen against seasonal and pandemic influenza, the company has revealed.The French firm presented its …
Jardiance scores more cardiovascular outcomes data
November 10, 2015Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes
A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …
Health minister criticised for blocking Off-Patent Drugs Bill debate
November 9, 2015Research and Development, Sales and Marketing Alistair Burt, Breast Cancer Now, MS Society, Off-Patent Drugs Bill
A Parliamentary Bill backing the wider use of off-patent drugs has been kicked into the long grass after the Government …
EMA concludes HPV vaccines do not cause CRPS or POTS
November 9, 2015Sales and Marketing EMA, HPV, HPV vaccine, PRAC, complex regional pain syndrome, drug safety, postural orthostatic tachycardia syndrome
The European Medicines Agency says there is no evidence from a detailed scientific review of reports linking complex regional pain …
Medicines Patent Pool to include hep C and TB drugs
November 9, 2015Sales and Marketing Medicines Patent Pool, affordable drugs, hep C, hepatitis, hepatitis C, medicines access, tuberculosis
The Medicines Patent Pool has expanded to include a mandate to make treatments for hepatitis C and tuberculosis affordable and …
Governments and industry ‘combining to stall drug development’
November 9, 2015Research and Development, Sales and Marketing BMJ, R&D, drug development
Both government and industry practices are responsible for the innovation deficit in the pharmaceutical sector, meaning that “the majority of …
Pfizer to double patient assistance allowance in the US
November 9, 2015Sales and Marketing Drug pricing, Pfizer
Pfizer says it will double the allowable income level for its RxPathways patient assistance program in the US with immediate …
GSK asthma drug Nucala gets FDA approval
November 6, 2015GSK, Nucala, asthma, eosinophils, mepolizumab
GlaxoSmithKline has received approval from the FDA for Nucala as an add-on maintenance treatment of patients with severe asthma aged …
Boehringer announces board changes, chairman’s retirement
November 6, 2015Medical Communications, Sales and Marketing
Boehringer Ingelheim has announced that Professor Andreas Barner will retire as chairman of the Board of Managing Directors on 30 …
UK doctors embracing technology, but not for their patients, survey reveals
November 6, 2015Medical Communications, Research and Development
A global online survey of doctors released by market research agency Cello Health Insight has indicated that although UK doctors …
Top 5 pharma companies’ Q3 results
November 6, 2015Medical Communications, Sales and Marketing financial results, revenue, sales
The leading pharma players have been able to report largely positive financial results to their shareholders in the third quarter …
AstraZeneca acquires ZS Pharma for $2.7bn, announces Q3 results
November 6, 2015Medical Communications AstraZeneca, M&A, MA, ZS Pharma, ZS-9, acquisitions, financial results, hyperkalaemia, mergers
AstraZeneca has announced its acquisition of ZS Pharma for an all-cash total of $2.7 billion. In the latest mega-money deal …
Sanofi buys in new diabetes drug
November 6, 2015Medical Communications, Research and Development, Sales and Marketing Lexicon Pharma, SGLT2, SGLT2 inhibitors, Sanofi, sotagliflozin
Sanofi has paid an initial $300 million for collaboration and license agreement to develop sotagliflozin, one of a newer class …
Brandicourt sets out Sanofi’s long-term vision
November 6, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, olivier brandicourt, pharma strategy
Sanofi has pledged to plough the money saved from its business restructure into R&D investment, to bring 18 new products …
Merck and Pfizer begin new Phase III avelumab trial in lung cancer
November 5, 2015Medical Communications, Research and Development Merck, Pfizer, avelumab, lung cancer, non-small cell lung cancer
Merck and Pfizer have commenced an international Phase III study of the investigational cancer immunotherapy avelumab in patients with non-small …
New treatments to boost dry eye drug market – if approved
November 5, 2015Sales and Marketing Allergan, Ikervis, Restasis, Shire, cyclosporine, dry eye disease, dry eye syndrome, lifitegrast
The global market for treatments for dry eye syndrome will double in value to an estimated $4.6 billion by 2024, …
Featured market report: Summary of dry eye syndrome
November 5, 2015dry eye disease, dry eye syndrome, lifitegrast
This report provides the current prevalent population for dry eye syndrome across seven major markets.It includes data for the USA, …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
